NeuroOne Appoints Veteran Med-Tech Analyst Jason Mills to Board of Directors

NeuroOne Medical Technologies Corporation announced the appointment of Jason Mills to its Board of Directors, effective December 18, 2025. Mills currently serves as Executive Vice President of Strategy at Penumbra, Inc., a leading thrombectomy company, where he oversees long-range planning, financial planning and analysis, business development, and investor relations.

Prior to his role at Penumbra, Mills spent over two decades as a dedicated medical technology investment analyst. He served as Managing Director and head of the medical technology equity research practice at Canaccord Genuity for more than 13 years, where he prepared financial models and forecasts, published research, and conducted due diligence on numerous public and private companies in the sector. His analytical work earned him recognition as the #2 ranked Medical Devices analyst in The Wall Street Journal's 2011 'Best on the Street' Survey and #1 in the Medical Products segment of Forbes 2010 Best Brokerage Analysts.

Dave Rosa, CEO of NeuroOne, stated that Mills brings unparalleled experience and insights in medical technology from both corporate and investment analyst perspectives. Rosa emphasized that Mills' firsthand knowledge of the industry, combined with his investment and capital markets expertise, will serve as a critical resource as NeuroOne progresses toward its clinical and corporate goals. The company is developing minimally invasive and high-definition solutions for EEG recording, monitoring, ablation, drug delivery, and stimulation for patients suffering from neurological disorders including epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain.

Paul Buckman, Chairman of the Board of Directors, noted that Mills will serve on the Compensation and Nominating & Corporate Governance Committees while helping the company expand its reach in transforming neurological disorder diagnosis and treatment. This appointment comes as NeuroOne continues to develop technologies that may improve patient outcomes and reduce procedural costs, with potential future applications in areas such as depression, mood disorders, pain management, incontinence, high blood pressure, and artificial intelligence.

The addition of a board member with Mills' specific background in medical technology analysis and corporate strategy signals NeuroOne's focus on strengthening its governance and strategic direction as it commercializes its neurological solutions. For investors and industry observers, this move suggests increased attention to financial discipline, market positioning, and shareholder value creation within the competitive medical technology sector. The company's technologies address significant unmet needs in neurological care, where improved diagnostic and treatment options could substantially impact patient quality of life and healthcare system efficiency. More information about NeuroOne's work is available at https://nmtc1.com.